Skip to Content
Merck
  • Cellular delivery of dinucleotides by conjugation with small molecules: targeting translation initiation for anticancer applications.

Cellular delivery of dinucleotides by conjugation with small molecules: targeting translation initiation for anticancer applications.

Chemical science (2021-08-12)
Natalia Kleczewska, Pawel J Sikorski, Zofia Warminska, Lukasz Markiewicz, Renata Kasprzyk, Natalia Baran, Karina Kwapiszewska, Aneta Karpinska, Jaroslaw Michalski, Robert Holyst, Joanna Kowalska, Jacek Jemielity
ABSTRACT

Targeting cap-dependent translation initiation is one of the experimental approaches that could lead to the development of novel anti-cancer therapies. Synthetic dinucleoside 5',5'-triphosphates cap analogs are potent antagonists of eukaryotic translation initiation factor 4E (eIF4E) in vitro and could counteract elevated levels of eIF4E in cancer cells; however, transformation of these compounds into therapeutic agents remains challenging - they do not easily penetrate into cells and are susceptible to enzymatic cleavage. Here, we tested the potential of several small molecule ligands - folic acid, biotin, glucose, and cholesterol - to deliver both hydrolyzable and cleavage-resistant cap analogs into cells. A broad structure-activity relationship (SAR) study using model fluorescent probes and cap-ligand conjugates showed that cholesterol greatly facilitates uptake of cap analogs without disturbing the interactions with eIF4E. The most potent cholesterol conjugate identified showed apoptosis-mediated cytotoxicity towards cancer cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cholesteryl-TEG azide